Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen

Pain

Volumn 136, Issue 1-2, 2008, Pages 150-157

  Vranken, J H ^a   Dijkgraaf, M G W ^b   Kruis, M R ^a   van der Vegt, M H ^a   Hollmann, M W ^a   Heesen, M ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Hospital of Bamberg   (Germany)

Author keywords

Central neuropathic pain; Pregabalin; Quality of life

Indexed keywords

ACETYLSALICYLIC ACID; BACLOFEN; BUPRENORPHINE; CARBAMAZEPINE; DICLOFENAC; FENTANYL; IBUPROFEN; MIRTAZAPINE; OXYCODONE; PAROXETINE; PLACEBO; PREGABALIN; TRAMADOL;

ADULT; ANALGESIA; ARTICLE; BRAIN INJURY; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERANCE; HEALTH STATUS; HUMAN; INTELLECT; MAJOR CLINICAL STUDY; NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; SOMNOLENCE; SPINAL CORD INJURY; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

CENTRAL NERVOUS SYSTEM DISEASES; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE;

EID: 41749093436     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2007.06.033     Document Type: Article

References (26)

1. Ballantine J.C., and Mao J. Opioid therapy for chronic pain. N Engl J Med 349 (2003) 1943-1953
2. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 92 (2001) 147-157
3. Cassel E.J. The nature of suffering. N Engl J Med 306 (1982) 639-645
4. Chibnall J.T., and Tait R.C. The Pain Disability Index: factor structure and normative data. Arch Phys Med Rehabil 75 (1994) 1082-1086
5. Dworkin R.H., Backonja M., Rowbotham M.C., Allen R.R., Argoff C.R., Bennett G.J., et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60 (2003) 1524-1534
6. Eide P.K. Pathophysiological mechanisms of central neuropathic pain after spinal cord injury. Spinal Cord 36 (1998) 601-612
7. EuroQol group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-209
8. Farrar J.T., Young Jr. J.P., LaMoreaux L., Werth J.L., and Poole M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001) 149-158
9. Fink K., Dooley D.J., Meder W.P., Suman-Chauhan N., Duffy S., Clusman H., et al. Inhibition of neuronal Ca2+-influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42 (2002) 229-236
10. Finnerup N.B., and Jensen T.S. Spinal cord injury pain - mechanisms and treatment. Eur J Neurol 11 (2004) 73-82
11. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., and Sindrup S.H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118 (2005) 289-305
12. Freynhagen R., Strojek K., Griesing T., Whalen E., and Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 (2005) 254-263
13. Gilron I., and Flatters S.J. Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag 11 (2006) 16A-29A
14. Haythornthwaite J.A., and Benrud-Larson L.M. Psychological aspects of neuropathic pain. Clin J Pain 16 (2000) S101-S105
15. Jensen T.S., and Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 102 (2003) 1-8
16. Kind P., Dolan P., Gudex C., and Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316 (1998) 736-741
17. McHorney C.A., Ware Jr. J.E., Lu J.F., and Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions and reliability across diverse patient groups. Med Care 32 (1992) 40-66
18. Millan M.J. The induction of pain: an integrative review. Prog Neurobiol 57 (1999) 1-164
19. Nicholson B.D. Evaluation and treatment of central pain syndromes. Neurology 62 (2004) S30-S36
20. Rowbotham M.C., Twilling L., Davies P.S., Reisner L., Taylor K., and Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348 (2003) 1223-1232
21. Saarto T., and Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev (2005) 10.1002/14651858 Art. No.: CD005454
22. Siddall P.J., Cousins M.J., Otto A., Griesing T., Chambers R., and Murphy T.K. Pregabalin in central neuropathic pain associated with spinal cord injury. Neurology 67 (2006) 1792-1800
23. Siddall P.J., McClelland J.M., Rutkowski S.B., and Cousins M.J. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 103 (2003) 249-257
24. Sindrup S.H., Otto M., Finnerup N.B., and Jensen T.S. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 96 (2005) 399-409
25. Vranken J.H., Dijkgraaf M.G.W., Kruis M.R., van Dasselaar N.T., and van der Vegt M.H. Iontophoretic administration of S(+)-ketamine in Patients with intractable Central Pain: a Placebo-Controlled Trial. Pain 118 (2005) 224-231
26. Yaksh T.L. Calcium channels as therapeutic targets in neuropathic pain. J Pain 7 (2006) S13-S30